Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s key product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co.'s second product candidate is KO-947, a selective small molecule inhibitor of extracellular signal related kinase, which Co. is developing as a potential treatment for patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway. Co.'s third product candidate is KO-539, a selective small molecule inhibitor of the menin-mixed lineage leukemia, protein-protein interaction. The KURA stock yearly return is shown above.
The yearly return on the KURA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KURA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|